Breast Cancer Coverage From Every Angle

Sherene Loi, MD, PhD, and Lisa A. Carey, MD, on TNBC: Combination Immune Checkpoint Inhibitor Therapy

Posted: Thursday, October 25, 2018

Sherene Loi, MD, PhD, of the Peter MacCallum Cancer Centre, and Lisa A. Carey, MD, of the University of North Carolina, discuss the phase III IMpassion 130 trial testing the first-line combination of the PD-L1 inhibitor atezolizumab plus nab-paclitaxel in metastatic triple-negative breast cancer, and how the findings relate to the NCCN Guidelines.

By continuing to browse this site you permit us and our partners to place identification cookies on your browser and agree to our use of cookies to identify you for marketing. Read our Privacy Policy to learn more.